ArticleBlood cancer journal2016
Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myeloma.
Article in Blood cancer journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial.Journal of hematology & oncology · 2019Trial
- Prognostic impact of focal lesion location and persistence in multiple myeloma: insights from serial PET/DWI imaging.Blood advances · 2025Article
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states.Nature communications · 2022Article
- PHF19 inhibition as a therapeutic target in multiple myeloma.Current research in translational medicine · 2021Article
- Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns.Blood cancer journal · 2020Article
- The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype.Haematologica · 2017Article
Corrections and comments
- Erratum for
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.